Free Trial
NASDAQ:CDNA

CareDx Q2 2025 Earnings Report

CareDx logo
$19.22 -0.27 (-1.39%)
As of 11:39 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CareDx EPS Results

Actual EPS
N/A
Consensus EPS
$0.12
Beat/Miss
N/A
One Year Ago EPS
N/A

CareDx Revenue Results

Actual Revenue
N/A
Expected Revenue
$90.72 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

CareDx Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, July 30, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

CareDx Earnings Headlines

CareDx, Inc (CDNA) Shares March Higher, Can It Continue?
Banks aren’t ready for this altcoin—are you?
Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly positioned to fill it…
See More CareDx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CareDx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CareDx and other key companies, straight to your email.

About CareDx

CareDx (NASDAQ:CDNA) engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

View CareDx Profile

More Earnings Resources from MarketBeat